From emerging agents to biomarkers: Integrating scientific advances into MS management

Abstract

Ongoing advances in the science of multiple sclerosis (MS) are contributing to improvements in the care of patients by slowing disease progression and disability. Advances in understanding the immunopathogenesis of MS are leading towards earlier diagnosis, better treatment, and the development of biomarkers of disease activity. As the inflammatory processes involved in MS have been defined, more biomarkers with potential clinical utility have been identified. The emergence of oral therapies and less frequent dosing schedules for injectable drugs are also changing the management of MS. These changes in treatment show promise for improving adherence to therapy thus, lessening the negative impact on outcomes associated with poor adherence. However, with all these advances, decisions regarding when to initiate treatment and which agents to use, along with deliberations on long-term management, are increasingly complex and difficult for physicians. This supplement discusses the advances in the science of MS and their application in the complex clinical decision-making process to provide better patient management and optimize outcomes. © 2013 by the Consortium of Multiple Sclerosis Centers and Rehabilitation in Multiple Sclerosis.